Evidence map›Paper›PMID 33857224›Full record

ArticlePloS one2021

Can predicting COVID-19 mortality in a European cohort using only demographic and comorbidity data surpass age-based prediction: An externally validated study.

Avishek Chatterjee, Guangyao Wu, Sergey Primakov, Cary Oberije, Henry Woodruff, Pieter Kubben, Ronald Henry, Marcel J H Aries, Martijn Beudel, Peter G Noordzij and 14 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Is there still hesitancy towards SARS-CoV-2 vaccination among people with neurological disease- a survey of the NeuroCOVID-19 task force of the European Academy of Neurology.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Observational
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Avishek ChatterjeeThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0003-3536-670X
Guangyao WuThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands.
Sergey PrimakovThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands.
Cary OberijeThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands.
Henry WoodruffThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands.
Pieter KubbenDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.ORCID 0000-0002-8059-523X
Ronald HenryDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Marcel J H AriesDepartment of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.
Martijn BeudelDepartment of Neurology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Peter G NoordzijDepartment of Anesthesiology and Intensive Care, St Antonius Hospital, Nieuwegein, The Netherlands.
Tom DormansDepartment of Intensive Care, Zuyderland Medical Center, Heerlen, The Netherlands.
Niels C Gritters van den OeverDepartment of Intensive Care, Treant Zorggroep, Emmen, The Netherlands.
Joop P van den BerghDepartment of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands.
Caroline E WyersDepartment of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands.ORCID 0000-0001-7662-3990
Suat SimsekDepartment of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.ORCID 0000-0001-8942-1503
Renée DoumaDepartment of Internal Medicine, Flevoziekenhuis, Almere, The Netherlands.
Auke C ReidingaDepartment of Intensive Care, Martiniziekenhuis, Groningen, The Netherlands.
Martijn D de KruifDepartment of Pulmonary Medicine, Zuyderland Medical Center, Heerlen, The Netherlands.
Julien GuiotDepartment of Respiratory Medicine, CHU of Liège, Liège, Belgium.
Anne-Noelle FrixDepartment of Respiratory Medicine, CHU of Liège, Liège, Belgium.
Renaud LouisDepartment of Respiratory Medicine, CHU of Liège, Liège, Belgium.
Michel MoutschenDepartment of Infectiology, CHU of Liège, Liège, Belgium.
Pierre LovinfosseNuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liège, Liège, Belgium.
Philippe LambinThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo establish whether one can build a mortality prediction model for COVID-19 patients based solely on demographics and comorbidity data that outperforms age alone. Such a model could be a precursor to implementing smart lockdowns and vaccine distribution strategies.

methodsThe training cohort comprised 2337 COVID-19 inpatients from nine hospitals in The Netherlands. The clinical outcome was death within 21 days of being discharged. The features were derived from electronic health records collected during admission. Three feature selection methods were used: LASSO, univariate using a novel metric, and pairwise (age being half of each pair). 478 patients from Belgium were used to test the model. All modeling attempts were compared against an age-only model.

resultsIn the training cohort, the mortality group's median age was 77 years (interquartile range = 70-83), higher than the non-mortality group (median = 65, IQR = 55-75). The incidence of former/active smokers, male gender, hypertension, diabetes, dementia, cancer, chronic obstructive pulmonary disease, chronic cardiac disease, chronic neurological disease, and chronic kidney disease was higher in the mortality group. All stated differences were statistically significant after Bonferroni correction. LASSO selected eight features, novel univariate chose five, and pairwise chose none. No model was able to surpass an age-only model in the external validation set, where age had an AUC of 0.85 and a balanced accuracy of 0.77.

conclusionWhen applied to an external validation set, we found that an age-only mortality model outperformed all modeling attempts (curated on www.covid19risk.ai) using three feature selection methods on 22 demographic and comorbid features.

Indexed as

AgedAged, 80 and overAge FactorsBelgiumCohort StudiesCommunicable Disease ControlComorbidityCOVID-19Electronic Health RecordsFemaleHospitalizationHumansMaleMiddle AgedNetherlandsPrognosis

Identifiers

PMID33857224
PMCPMC8049248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.